Short-acting beta-agonists (SABAs) are indicated for use in all stages of COPD according to the GOLD COPD guidelines. They provide immediate relief by dilating the airways and are distinct from other long-term medications.
According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD COPD guidelines), short-acting beta-agonists (SABAs) are indicated for use in all stages of COPD. These medications are bronchodilators that provide quick relief of symptoms by relaxing constricted airways, thus facilitating easier breathing.
In contrast, long-acting beta-agonists (LABAs), inhaled corticosteroids (ICS), and long-acting muscarinic antagonists (LAMAs) are typically prescribed based on the severity and progression of the disease. While SABAs offer fast relief during acute episodes, the other medications are generally used for long-term control to prevent COPD exacerbations. It's essential for individuals with COPD to discuss their symptoms with a healthcare provider to determine the most appropriate treatment plan.